Aratana Therapeutics (PETX) Hits New 52-Week Low at $4.51

Shares of Aratana Therapeutics Inc (NASDAQ:PETX) reached a new 52-week low during mid-day trading on Monday . The stock traded as low as $4.51 and last traded at $4.51, with a volume of 184475 shares. The stock had previously closed at $4.61.

PETX has been the topic of several recent analyst reports. CL King initiated coverage on shares of Aratana Therapeutics in a research note on Wednesday, December 27th. They issued a “neutral” rating on the stock. HC Wainwright set a $10.00 target price on shares of Aratana Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, January 16th. Stifel Nicolaus reiterated a “hold” rating and issued a $6.00 target price on shares of Aratana Therapeutics in a research note on Monday, December 18th. Jefferies Group reiterated a “buy” rating and issued a $8.00 target price on shares of Aratana Therapeutics in a research note on Friday, November 3rd. Finally, Zacks Investment Research cut shares of Aratana Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, January 17th. Three analysts have rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $8.55.

The company has a debt-to-equity ratio of 0.26, a current ratio of 3.42 and a quick ratio of 3.08. The company has a market cap of $195.65, a P/E ratio of -3.13 and a beta of 3.06.

In other news, CEO Peter Steven St sold 19,367 shares of the firm’s stock in a transaction on Tuesday, January 30th. The shares were sold at an average price of $4.77, for a total transaction of $92,380.59. Following the sale, the chief executive officer now owns 672,259 shares in the company, valued at approximately $3,206,675.43. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Healthcare Master Fun Broadfin sold 116,516 shares of the firm’s stock in a transaction on Wednesday, November 29th. The shares were sold at an average price of $6.53, for a total transaction of $760,849.48. The disclosure for this sale can be found here. Insiders sold a total of 1,106,399 shares of company stock worth $6,437,271 over the last quarter. Corporate insiders own 5.20% of the company’s stock.

Several institutional investors have recently bought and sold shares of the company. Broadfin Capital LLC raised its position in shares of Aratana Therapeutics by 40.3% during the 2nd quarter. Broadfin Capital LLC now owns 5,184,942 shares of the biopharmaceutical company’s stock valued at $37,487,000 after buying an additional 1,489,500 shares in the last quarter. Janus Henderson Group PLC raised its position in shares of Aratana Therapeutics by 0.6% during the 3rd quarter. Janus Henderson Group PLC now owns 1,801,381 shares of the biopharmaceutical company’s stock valued at $11,042,000 after buying an additional 10,551 shares in the last quarter. AWM Investment Company Inc. raised its position in Aratana Therapeutics by 49.4% in the 2nd quarter. AWM Investment Company Inc. now owns 1,587,620 shares of the biopharmaceutical company’s stock worth $11,478,000 after purchasing an additional 525,000 shares during the period. Alyeska Investment Group L.P. raised its position in Aratana Therapeutics by 10.5% in the 3rd quarter. Alyeska Investment Group L.P. now owns 964,116 shares of the biopharmaceutical company’s stock worth $5,910,000 after purchasing an additional 91,763 shares during the period. Finally, General American Investors Co. Inc. raised its position in Aratana Therapeutics by 40.2% in the 3rd quarter. General American Investors Co. Inc. now owns 867,600 shares of the biopharmaceutical company’s stock worth $5,318,000 after purchasing an additional 248,940 shares during the period. Hedge funds and other institutional investors own 73.53% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece was first reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be read at https://sportsperspectives.com/2018/02/05/aratana-therapeutics-petx-hits-new-52-week-low-at-4-51.html.

About Aratana Therapeutics

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply